Cognitive-behavioral therapy for post COVID-19 condition: A pilot randomized controlled trial.

J Psychosom ResJul 7, 2026 (epub)
Clinical ResearchPsychiatry

Karoline Sophie Sauer, Anne-Kathrin Bräscher, Sylvan Germer et al.

✦ AI-curated · Sources linked

In 30 seconds

This pilot randomized controlled trial evaluated the feasibility and efficacy of cognitive-behavioral therapy (CBT) for post COVID-19 condition (PCC) in 52 participants. Results indicated a significant medium-sized reduction in fatigue for the CBT group compared to a wait-list control (d = -0.58, p = .045), while the control group experienced increased somatic symptoms.

Key findings

  • CBT participants experienced a significant reduction in fatigue compared to the wait-list control (d = -0.58, p = .045).
  • The wait-list control group showed a significant increase in overall somatic symptoms (d = 0.60, p = .027).
  • Feasibility and treatment satisfaction for CBT were reported as good with few adverse effects.

Why it matters

The findings suggest that cognitive-behavioral therapy may be a viable treatment option for managing fatigue and somatic symptoms in patients with post COVID-19 condition, addressing an urgent need for effective interventions.

Source

PubMed · PMID 42435513

Published in J Psychosom Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.